Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix

Completed · Phase 2

Conditions studied: Cervical Cancer

In brief

RATIONALE: Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells in the cervix. PURPOSE: Phase II trial to study the effectiveness of interleukin-12 in treating patients who have advanced or recurrent cancer of the cervix.

Key facts

Study ID

NCT00003017

Run by

Eastern Cooperative Oncology Group

Starts

1997-07-01

Expected to finish

2005-08-01

Last updated by the study team

2013-06-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Hunterdon Regional Cancer Center — Flemington, New Jersey, United States
• CCOP - Northern New Jersey — Hackensack, New Jersey, United States
• NYU School of Medicine's Kaplan Comprehensive Cancer Center — New York, New York, United States
• University of Rochester Cancer Center — Rochester, New York, United States
• Albert Einstein Comprehensive Cancer Center — The Bronx, New York, United States
• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
• University of Pittsburgh Cancer Institute — Pittsburgh, Pennsylvania, United States
• Vanderbilt Cancer Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.